Is retatrutide a real medicine?

Retatrutide is an experimental compound in Phase 3 trials. It is not approved as a medicine by the MHRA, EMA or FDA. It is supplied as a research peptide for laboratory and analytical use only, not for human therapeutic use.

How is retatrutide different from tirzepatide?

Tirzepatide activates two receptors — GLP-1 and GIP. Retatrutide adds a third — glucagon. The triple-receptor activation produced a ~24% mean weight reduction in the Phase 2 trial, compared to tirzepatide's ~22% in SURMOUNT-1, despite retatrutide using a shorter 48-week schedule.

When will retatrutide be available?

Phase 3 trials (TRIUMPH-1 through 3) are running. First readout is expected H1 2026. MHRA approval typically follows 12-18 months after Phase 3 readout, putting realistic UK availability in 2027-2028 at earliest.

Can I buy retatrutide privately in the UK?

No. Retatrutide is not a licensed medicine in the UK. Private prescribers cannot legally prescribe it for human use. Research-grade material exists for laboratory work only and is not interchangeable with a regulated pharmaceutical product.

What is Retatrutide? Plain-English UK Explainer (2026)

One paragraph

Retatrutide is an experimental once-weekly injectable developed by Eli Lilly. It activates three different appetite-and-metabolism receptors at once — GLP-1, GIP and glucagon. Phase 2 data published in NEJM 2023 showed a ~24% mean body weight reduction at 48 weeks, the largest yet recorded for a metabolic peptide. It is currently in Phase 3 trials and is not approved as a medicine in the UK or anywhere else.

Why three receptors?

Earlier-generation drugs targeted only the GLP-1 receptor (semaglutide / liraglutide). Tirzepatide added GIP for a step-change in efficacy. Retatrutide adds glucagon — which increases the body's resting energy expenditure on top of the appetite suppression delivered by GLP-1 and GIP. The combined mechanism is hypothesised to attack body weight from both the energy-intake and energy-expenditure sides simultaneously.

Phase 2 evidence

The Jastreboff Phase 2 trial randomised 338 adults with obesity (no diabetes) to placebo or retatrutide at 1, 4, 8 or 12 mg weekly over 48 weeks. Placebo-adjusted weight reductions were -7.2%, -12.9%, -17.3% and -17.5% across the four active arms. Total observed reduction at 12 mg was approximately -24% — exceeding tirzepatide's SURMOUNT-1 result despite a shorter trial.

Open questions

Phase 2 showed a small dose-dependent heart-rate increase (3-6 bpm at 8 and 12 mg arms) that has not been seen with tirzepatide. Whether this persists or attenuates in larger Phase 3 cohorts, and how it interacts with cardiovascular outcomes, are open. Glucagon-receptor agonism could in principle worsen glycaemic control in type 2 diabetes — the TRIUMPH-2 trial is designed to address that.

FAQs

Is retatrutide a real medicine?: Retatrutide is an experimental compound in Phase 3 trials. It is not approved as a medicine by the MHRA, EMA or FDA. It is supplied as a research peptide for laboratory and analytical use only, not for human therapeutic use.
How is retatrutide different from tirzepatide?: Tirzepatide activates two receptors — GLP-1 and GIP. Retatrutide adds a third — glucagon. The triple-receptor activation produced a ~24% mean weight reduction in the Phase 2 trial, compared to tirzepatide's ~22% in SURMOUNT-1, despite retatrutide using a shorter 48-week schedule.
When will retatrutide be available?: Phase 3 trials (TRIUMPH-1 through 3) are running. First readout is expected H1 2026. MHRA approval typically follows 12-18 months after Phase 3 readout, putting realistic UK availability in 2027-2028 at earliest.
Can I buy retatrutide privately in the UK?: No. Retatrutide is not a licensed medicine in the UK. Private prescribers cannot legally prescribe it for human use. Research-grade material exists for laboratory work only and is not interchangeable with a regulated pharmaceutical product.